ATE306263T1 - Zusammensetzungen zur verabreichung eines cyclooxygenase-2-hemmers an tiere - Google Patents

Zusammensetzungen zur verabreichung eines cyclooxygenase-2-hemmers an tiere

Info

Publication number
ATE306263T1
ATE306263T1 AT00916179T AT00916179T ATE306263T1 AT E306263 T1 ATE306263 T1 AT E306263T1 AT 00916179 T AT00916179 T AT 00916179T AT 00916179 T AT00916179 T AT 00916179T AT E306263 T1 ATE306263 T1 AT E306263T1
Authority
AT
Austria
Prior art keywords
cyclooxygenase
inhibitor
administration
compositions
animals
Prior art date
Application number
AT00916179T
Other languages
English (en)
Inventor
J Timothy Keane
Joseph R Schuh
Alan L Scrivner
Original Assignee
Searle Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22409943&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE306263(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Searle Llc filed Critical Searle Llc
Application granted granted Critical
Publication of ATE306263T1 publication Critical patent/ATE306263T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Fodder In General (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT00916179T 1999-03-10 2000-03-09 Zusammensetzungen zur verabreichung eines cyclooxygenase-2-hemmers an tiere ATE306263T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12364499P 1999-03-10 1999-03-10
PCT/US2000/006097 WO2000053149A2 (en) 1999-03-10 2000-03-09 Method and composition for administering a cyclooxygenase-2 inhibitor

Publications (1)

Publication Number Publication Date
ATE306263T1 true ATE306263T1 (de) 2005-10-15

Family

ID=22409943

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00916179T ATE306263T1 (de) 1999-03-10 2000-03-09 Zusammensetzungen zur verabreichung eines cyclooxygenase-2-hemmers an tiere

Country Status (9)

Country Link
EP (2) EP1158977B1 (de)
JP (1) JP2002538189A (de)
AT (1) ATE306263T1 (de)
AU (1) AU778538B2 (de)
CA (1) CA2363590A1 (de)
DE (1) DE60023119T2 (de)
ES (1) ES2249253T3 (de)
NZ (1) NZ513965A (de)
WO (1) WO2000053149A2 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1679556A (zh) * 1999-12-08 2005-10-12 法马西亚公司 维得克西组合物
CO5261556A1 (es) * 1999-12-08 2003-03-31 Pharmacia Corp Composiciones inhibidoras de ciclooxigenasa-2 que tiene rapido acceso de efecto terapeutico
CA2394232C (en) * 1999-12-22 2009-06-09 Subhash Desai Dual-release compositions of a cyclooxygenase-2-inhibitor
WO2001091856A2 (en) * 2000-06-01 2001-12-06 Pharmacia Corporation Use of cox2 inhibitors for treating skin injury from exposure to ultraviolet radiation
US6982251B2 (en) 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
HU230435B1 (hu) 2001-01-26 2016-06-28 Merck Sharp & Dohme Corp Szubsztituált azetidinon vegyületek alkalmazása szitoszterinémia kezelésére
RS20100015A (sr) 2001-01-26 2010-12-31 Schering Corporation Kombinacija aktivatora receptora aktiviranog peroksizom- proliferatorom (ppar) fenofibrata sa inhibitorom apsorpcije sterola ezetimibom za vaskularne indikacije
US7071181B2 (en) 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
US7056906B2 (en) 2001-09-21 2006-06-06 Schering Corporation Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
CA2460340C (en) 2001-09-21 2011-02-15 Schering Corporation Methods and therapeutic combinations for the treatment of xanthoma using sterol absorption inhibitors
US7053080B2 (en) 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
JP2005522477A (ja) 2002-04-08 2005-07-28 グラクソ　グループ　リミテッド （２−（（２−アルコキシ）−フェニル）−シクロペント−１−エニル）芳香族炭素環式および複素環式酸および誘導体
AR040588A1 (es) 2002-07-26 2005-04-13 Schering Corp Formulacion farmaceutica que comprende un inhibidor de la absorcion del colesterol y un inhibidor de una hmg- co a reductasa
GB0225548D0 (en) 2002-11-01 2002-12-11 Glaxo Group Ltd Compounds
MXPA05004811A (es) 2002-11-06 2005-07-22 Schering Corp Inhibidores de absorcion de colesterol para el tratamiento de trastornos autoinmunes.
US7459442B2 (en) 2003-03-07 2008-12-02 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
CA2517571C (en) 2003-03-07 2011-07-05 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
MXPA05009501A (es) 2003-03-07 2005-10-18 Schering Corp Compuestos de azetidinona sustituidos, formulaciones y usos de los mismos para el tratamiento de hipercolesterolemia.
MXPA05009502A (es) 2003-03-07 2005-10-18 Schering Corp Compuestos de azetidinona sustituidos, formulaciones y usos de los mismos para el tratamiento de hipercolesterolemia.
DE602004002832T2 (de) 2003-05-07 2007-06-06 Osteologix A/S Behandlung von knorpel/knochen-erkrankungen mit wasserlöslichen strontiumsalzen

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5585504A (en) * 1994-09-16 1996-12-17 Merck & Co., Inc. Process of making cox-2 inhibitors having a lactone bridge
CA2223154A1 (en) * 1995-06-02 1996-12-05 G.D. Searle & Co. Heterocyclo substituted hydroxamic acid derivatives as cyclooxygenase-2 and 5-lipoxygenase inhibitors
US5756529A (en) * 1995-09-29 1998-05-26 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides for use in veterinary therapies
JP4346685B2 (ja) * 1996-10-21 2009-10-21 ユーロビタ アクティーゼルスカブ パルテニウム・インテグリフォリウム又はその部分若しくはそのエキス又はその成分を含有する医薬組成物、かかる植物材料の医薬製造のための使用、及びパルテニウム・インテグリフォリウムのエキスの製造方法
PL194717B1 (pl) * 1996-11-19 2007-06-29 Searle & Co Zastosowanie inhibitorów cyklooksygenazy-2 do wytwarzania leku do leczenia chorób związanych z rozwojem naczyń
DZ2479A1 (fr) * 1997-05-05 2003-02-01 Pfizer Composés inhibiteurs sélectifs de cox-2 anti-inflammatoires et compositions pharmaceutiques les contenant.

Also Published As

Publication number Publication date
EP1158977B1 (de) 2005-10-12
EP1158977A4 (de) 2003-09-03
EP1637137A3 (de) 2006-07-05
ES2249253T3 (es) 2006-04-01
NZ513965A (en) 2004-04-30
DE60023119D1 (de) 2006-02-23
CA2363590A1 (en) 2000-09-14
EP1637137A2 (de) 2006-03-22
JP2002538189A (ja) 2002-11-12
WO2000053149A2 (en) 2000-09-14
WO2000053149A3 (en) 2000-12-28
EP1158977A2 (de) 2001-12-05
AU3732600A (en) 2000-09-28
AU778538B2 (en) 2004-12-09
DE60023119T2 (de) 2006-07-20

Similar Documents

Publication Publication Date Title
ATE306263T1 (de) Zusammensetzungen zur verabreichung eines cyclooxygenase-2-hemmers an tiere
DE69909298D1 (de) Verfahren zur herstellung einer zusammensetzung zum schutz eines fleischfressenden haustieres gegen krankheiten des abnormalen kohlenhydrat-metabolismus
NZ333695A (en) Method for treating gastrointestinal damage with hyperimmunised milk and hyperimmunised egg
MY109928A (en) Fatty acid treatment
NZ519980A (en) Pet food composition for treating helicobacter species in pets
ID28060A (id) Pencegahan karang gigi dengan asam polikarboksilat
ATE323480T1 (de) Zusammensetzungen, enthaltend pinolensäure sowie deren verwendung zur gesundheitserhaltung
BR9507099A (pt) Forma de dosagem método de esterilização composição esterilizante e suplemento alimentar animal compreendendo nitrito acidificado como um agente anti-microbiano
WO2006002976A3 (en) Canine osteoarthritis diet formulation
PL1841743T3 (pl) Amidy kwasu 3-arylo-3-hydroksy-2-aminopropionowego, amidy kwasu 3-heteroarylo-3-hydroksy-2-aminopropionowego i powiązane związki o działaniu przeciwbólowym i/lub immunostymulacyjnym
MX230817B (en) Method of increasing fat firmness and improving meat quality in animals
ATE258435T1 (de) Pinolensäure gegen diabetes
MX2007001931A (es) Aditivo alimentario.
EP1550443A4 (de) Zusammensetzung gegen stressbedingte erkrankungen
PT1233678E (pt) Formulacoes zootecnicas que compreendem acidos biliares
DE60224878D1 (de) Hemmung von tyrophagus putrescentiae in tierfuttermitteln
EE200300406A (et) Meetod loomasööda lisandina kasutatava D-pantoteenhappe ja/või tema soolade saamiseks
EE200300405A (et) Meetod loomasööda lisandina kasutatava D-pantoteenhappe ja/või tema soolade saamiseks
AU6245801A (en) Food for slowing down feed intake speed in dogs
ATE355741T1 (de) Verfahren zur herstellung von nährstoffen, nährstoffe und verfahren zur abgabe von nährstoffen
MX2021015590A (es) Metodos y composiciones con beneficios renales para felinos.
JP2003246728A5 (de)
UA34330A (uk) Кормова добавка для птиці
EP1163903A3 (de) Methanal - Injektion zur Behandlung epidemischer Tierkrankheiten
WO2002038103A3 (en) Probiotic compositions and methods against bacterial infection in livestock animals

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties